Table 1.
Overall patient | Exposure group |
|||||||
---|---|---|---|---|---|---|---|---|
No medication | Muscle relaxant | Benzodiazepine | Opioid | Double threat | Triple threat | |||
Control Group | No medication | 2013 exposure w/ 2013 HD visit ≥1 |
2.42 (2.41-2.43) |
3.67 (3.66-3.68) |
5.63 (5.62-5.64) |
5.71 (5.69-5.72) |
8.52 (8.50-8.55) |
|
2014 exposure w/ 2014 HD visit ≥1 |
1.11 (1.10-1.11) |
3.43 (3.42-3.44) |
6.72 (6.71-6.73) |
11.47 (11.44-11.49) |
5.06 (5.04-5.08) |
|||
2013 exposure w/ 2014 HD visit ≥1 |
2.37 (2.36-2.38) |
3.11 (3.10-3.12) |
2.32 (2.32-2.32) |
5.59 (5.57-5.60) |
4.61 (4.59-4.63) |
|||
Muscle relaxant | 2013 exposure w/ 2013 HD visit ≥1 |
1.52 (1.51-1.52) |
2.33 (2.32-2.33) |
2.36 (2.35-2.37) |
3.52 (3.51-3.54) |
|||
2014 exposure w/ 2014 HD visit ≥1 |
3.10 (3.08-3.12) |
6.07 (6.04-6.10) |
10.36 (10.30-10.41) |
4.57 (4.54-4.60) |
||||
2013 exposure w/ 2014 HD visit ≥1 |
1.31 (1.31-1.32) |
0.98 (0.98-0.98) |
2.36 (2.35-2.37) |
1.95 (1.94-1.96) |
||||
Benzodiazepine | 2013 exposure w/ 2013 HD visit ≥1 |
1.53 (1.53-1.54) |
1.55 (1.55-1.56) |
2.32 (2.31-2.33) |
||||
2014 exposure w/ 2014 HD visit ≥1 |
1.96 (1.95-1.96) |
3.34 (3.33-3.35) |
1.48 (1.47-1.48) |
|||||
2013 exposure w/ 2014 HD visit ≥1 |
0.75 (0.74-0.75) |
1.80 (1.79-1.80) |
1.48 (1.48-1.49) |
|||||
Opioids | 2013 exposure w/ 2013 HD visit ≥1 |
1.01 (1.01-1.02) |
1.51 (1.51-1.52) |
|||||
2014 exposure w/ 2014 HD visit ≥1 |
2.42 (2.40-2.42) |
0.75 (0.75-0.76) |
||||||
2013 exposure w/ 2014 HD visit ≥1 |
2.41 (2.40-2.42) |
1.99 (1.98-2.00) |
||||||
Double threat | 2013 exposure w/ 2013 HD visit ≥1 |
1.50 (1.49-1.50) |
||||||
2014 exposure w/ 2014 HD visit ≥1 |
0.44 (0.44-0.44) |
|||||||
2013 exposure w/ 2014 HD visit ≥1 |
0.83 (0.82-0.83) |
|||||||
Triple threat | 2013 exposure w/ 2013 HD visit ≥1 |
|||||||
2014 exposure w/ 2014 HD visit ≥1 |
||||||||
2013 exposure w/ 2014 HD visit ≥1 |